Rockwell Medical sales skyrockets 20% to $19.1 million
Full story: https://grafa.com/en/news/united-states/rockwell-medical-q3-2026-sales-rise-20-percent
Key points
-
Rockwell Medical (NASDAQ:RMTI) reported third-quarter 2026 net sales of $19.1 million, up 20% from $15.9 million a year earlier.
-
Gross profit increased 37% to $3.1 million, while gross margin improved to 16% from 14%; quarterly net loss widened to $2.3 million.
-
The proposed combination with Vantive's hemodialysis business is projected by the company to generate annual revenue of $400 million–$450 million.
Rockwell Medical (NASDAQ:RMTI) reported third-quarter 2026 net sales of $19.1 million, up 20% year over year, while its net loss widened to $2.3 million, or $0.59 per share.
Revenue increased from $15.9 million a year earlier, while gross profit rose 37% to $3.1 million and gross margin improved to 16% from 14%.
Adjusted EBITDA recorded a loss of $267,000, compared with income of $50,000 a year earlier, while cash, cash equivalents and available-for-sale investments declined to $22.5 million from $24.8 million at June 30.
For the first nine months of 2026, revenue increased 7% to $54.2 million, gross profit rose 18% to $9.3 million, and net loss widened to $5.1 million from $4.8 million a year earlier.
Separately, Rockwell Medical agreed to acquire Vantive's global hemodialysis business for a $125 million base purchase price, with closing expected in mid-2027, and estimated that the combined business could generate annual revenue of $400 million–$450 million.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
